Development of standard clinical endpoints for use in dengue interventional trials.

• Egile Nagusiak: Kay M Tomashek (Egilea), Bridget Wills (Egilea), Lucy Chai See Lum (Egilea), Laurent Thomas (Egilea), Anna Durbin (Egilea), Yee-Sin Leo (Egilea), Norma de Bosch (Egilea), Elsa Rojas (Egilea), Kim Hendrickx (Egilea), Martin Erpicum (Egilea), Liane Agulto (Egilea), Thomas Jaenisch (Egilea), Hasitha Tissera (Egilea), Piyarat Suntarattiwong (Egilea), Beth Ann Collers (Egilea), Derek Wallace (Egilea), Alexander C Schmidt (Egilea), Alexander Precioso (Egilea), Federico Narvaez (Egilea), Stephen J Thomas (Egilea), Robert Edelman (Egilea), João Bosco Siqueira (Egilea), M Cristina Cassetti (Egilea), Walla Dempsey (Egilea), Duane J Gubler (Egilea)
• Formatua: Liburua
• Argitaratua: Public Library of Science (PLoS), 2018-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Dengue is a major public health problem worldwide. Although several drug candidates have been evaluated in randomized controlled trials, none has been effective and at present, early recognition of severe dengue and timely supportive care are used to reduce mortality. While the first dengue vaccine...